How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
4 links0 made here, not in the record8 judgments2 judges (our rules as one)1 record change seen
Model not recordedOur rulesRecord updated on ClinicalTrials.gov
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Anti-EGFR Antibody-drug Conjugate CPO301
From the registry record2 judgments on this linkRole in the study, from the registry to what was judged
RegistryEntry “SYS6010 injection”the record gives no role
→judged=agreesHow the 2 judgments split100%of judgments with a known value say Tested
Tested · 2
All judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| Oct 19 | The record itself | ClinicalTrials.gov record | Version of 2026-10-19 | Record change |
| Nov 1 | Anti-EGFR Antibody-drug Conjugate CPO301 | A model not recorded | Tested | Current |
| Nov 1 | Enlonstobart | A model not recorded | Background | Current |
| Nov 1 | Pembrolizumab | A model not recorded | Background | Current |
| Nov 14 | Squamous Cell Carcinoma of Head and Neck | Our condition-kind rule | Finest filed term | Current |
| Nov 18 | Anti-EGFR Antibody-drug Conjugate CPO301 | Our role rule | Tested | Agrees |
| Nov 18 | Enlonstobart | Our role rule | Tested | Overridden |
| Nov 18 | Pembrolizumab | Our role rule | Background | Agrees |
| As of now | Squamous Cell Carcinoma of Head and Neck | Our main-condition rule (R9) | Main condition | Current |